Relationship between plasma acylation stimulating protein and obese nonalcoholic fatty liver disease

Abstract

Abstract: Objective To investigate the relationship between plasma acylation stimulating protein (ASP) and obesity in obese patients with nonalcoholic fatty liver disease (NAFLD).Methods A total of 72 obese and non-obese NAFLD patients in our hospital from 2017 to 2019 were selected as the research objects, and 60 healthy people who passed the physical examination in the same period in our hospital were selected. The serum or plasma biochemical indexes of the three groups were compared, and the correlation between ASP and body mass index (BMI) in NAFLD patients was analyzed by Pearson.Results Compared with the control group, the levels of plasma ASP and other glucose and lipid metabolism in obese and non-obese NAFLD patients were significantly increased (P<0.01), while compared with non-obese NAFLD group, the level of ASP and other glycolipid metabolism indexes in obese NAFLD patients increased more significantly (P<0.01).Conclusion The content of ASP in plasma of obese NAFLD patients is higher, which may be related to obesity and blood lipid metabolism.

Key words: Obese nonalcoholic fatty liver disease, Plasma acylation promoting protein, Lipid metabolism

LI Xiao-xiang, GU Xiao-dan, XU Wei-dong. Relationship between plasma acylation stimulating protein and obese nonalcoholic fatty liver disease[J]. Chinese Hepatolgy, 2021, 26(8): 913-916.

References

[1] Friedman SL,Neuschwander-Tetri BA,Rinella M,et al. Mechanisms of NAFLD development and therapeutic strategies.Nat Med,2018,24:908-922.
[2] Hlavat? P,Kunesová M. Acylation stimulating protein-its role in control of metabolism in the adipose tissue. Cas Lek Cesk,2006,145:14-18.
[3] Rato Q,Cianflone K,Sniderman A. Adipsin system--acylation-stimulation protein (ASP) and hyperapo-B. Rev Port Cardiol,1996,15:433-438.
[4] Fisette A,Lapointe M,Cianflone K. Obesity-inducing diet promotes acylation stimulating protein resistance. Biochem Biophys Res Commun,2013,437:403-407.
[5] Tom FQ,Gauvreau D,Lapointe M,et al. Differential chemoattractant response in adipocytes and macrophages to the action of acylation stimulating protein.Eur J Cell Biol,2013,92:61-69.
[6] 李红娟,杨柳,张楠.身体质量指数作为肥胖筛查标准的判别准确性评价.中国预防医学杂志,2014,15:571-575.
[7] Manne V,Handa P,Kowdley KV. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.Clin Liver Dis, 2018,22:23-37.
[8] Castellano-Castillo D,Moreno-Indias I,Fernandez-Garcia JC,et al. Complement Factor C3 Methylation and mRNA Expression Is Associated to BMI and Insulin Resistance in Obesity. Genes (Basel), 2018,9:410-419.
[9] Ursini F,Russo E,Mauro D,et al. Complement C3 and fatty liver disease in Rheumatoid arthritis patients: a cross-sectional study.Eur J Clin Invest,2017,47:728-735.
[10] Ursini F, Abenavoli L. The Emerging Role of Complement C3 as A Biomarker of Insulin Resistance and Cardiometabolic Diseases: Preclinical and Clinical Evidence. Rev Recent Clin Trials,2018,13:61-68.
[11] Pan B,Wan X,Ma M,et al. Complement C3 and Nonalcoholic Fatty Liver Disease in Chronic Kidney Disease Patients:A Pilot Study.Kidney Blood Press Res,2020,45:61-69.
[12] Xu C,Chen Y, Xu L,et al. Serum complement C3 levels are associated with nonalcoholic fatty liver disease independently of metabolic features in Chinese population.Sci Rep,2016,6:23279-23285.
[13] Mishra S (a),Gupta V,Mishra S,et al. Association of acylation stimulating protein and adiponectin with metabolic risk marker in North Indian obese women.Diabetes Metab Syndr,2019,13:2987-2990.
[14] Mishra S (b), Gupta V,Mishra S,et al. An increase level of acylation stimulating protein is correlated with metabolic risk markers in North Indian obese women.Diabetes Metab Syndr,2017,11:S797-S801.
[15] Yesilova Z,Ozata M,Oktenli C,et al. Increased acylation stimulating protein concentrations in nonalcoholic fatty liver disease are associated with insulin resistance.Am J Gastroenterol,2005,100:842-849.
[16] Sookoian S,Pirola C J. Liver enzymes, metabolomics and genome-wide association studies: from systems biology to the personalized medicine.World J Gastroenterol,2015,21:711-25.
[17] Yang H,Li D,Song X,et al. Joint associations of serum uric acid and ALT with NAFLD in elderly men and women: a Chinese cross-sectional study.J Transl Med,2018,16:285-295.
[18] Cianflone K,Zhang XJ,Genest JJr,et al. Plasma acylation-stimulating protein in coronary artery disease.Arterioscler Thromb Vasc Biol,1997,17:1239-1244.
[19] Maslowska M,Vu H,Phelis S,et al. Plasma acylation stimulating protein, adipsin and lipids in non-obese and obese populations.Eur J Clin Invest,1999,29:679-686.
[20] Cianflone K,Lu H,Smith J,et al. Adiponectin, acylation stimulating protein and complement C3 are altered in obesity in very young children.Clin Endocrinol (Oxf),2005,62:567-572.
[21] Koistinen HA,Vidal H,Karonen SL,et al. Plasma acylation stimulating protein concentration and subcutaneous adipose tissue C3 mRNA expression in nondiabetic and type 2 diabetic men.Arterioscler Thromb Vasc Biol,2001,21:1034-1039.
[22] Ozata M, Gungor D,Turan M,et al. Improved glycemic control increases fasting plasma acylation-stimulating protein and decreases leptin concentrations in type Ⅱ diabetic subjects. J Clin Endocrinol Metab,2001,86:3659-3664.